Antitumoral activity of Ficus carica L. on colorectal cancer cell lines

Soltana, Hala; Pinon, Aline; Limami, Youness; Zaid, Younes; Khalki, Loubna; Zaïd, Nabil; Salah, D. Ben; Sabitaliyevich, Uteuliyev Yerzhan; Simon, Alain; Liagre, Bertrand; Hammami, Mohamed

doi:10.14715/cmb/2019.65.6.2

Cited by 32 publications

(18 citation statements)

References 36 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Boyacioglu et al demonstrated the cytotoxicity of n-hexane extracts of the dried leaves of two fig cultivars in PC3 human prostate cancer cells [20]. Soltana et al investigated the antitumor activity of F. carica extracts (peel, pulp, leaves, whole fruit) and latex on HCT-116 and HT-29 human colorectal cells and found that the extracts and latex have antiproliferative effects and induce apoptosis in cancer cells [21]. Purnamasari et al examined the anticancer activity of F. carica leaf and fruit methanolic extracts using Huh7it liver cancer cells and their studies revealed a higher percentage of Huh7it apoptosis and necrosis in leaf extracts than in fruit extracts [22].…”

Section: Introductionmentioning

confidence: 99%

Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets

et al. 2021

View full text Add to dashboard Cite

Ficus carica L., commonly known as fig, has been used in traditional medicine for metabolic disorders, cardiovascular diseases, respiratory diseases and cancer. Various bioactive compounds have been previously isolated from the leaves, fruit, and bark, which have different pharmacological properties, but the anticancer mechanisms of this plant are not known. In the current study we focused on understanding the probable mechanisms underlying the anticancer activity of F. carica plant extracts by molecular docking and dynamic simulation approaches. We evaluated the drug-likeness of the active constituents of the plant and explored its binding affinity with selected anticancer drug target receptors such as cyclin-dependent kinase 2 (CDK-2), cyclin-dependent kinase 6 (CDK-6), topoisomerase-I (Topo I), topoisomerase-II (Topo II), B-cell lymphoma 2 (Bcl-2), and vascular endothelial growth factor receptor 2 (VEGFR-2). In silico toxicity studies revealed that thirteen molecules out of sixty-eight major active compounds in the plant extract have acceptable drug-like properties. Compound 37 (β-bourbonene) has a good binding affinity with the majority of drug targets, as revealed by molecular docking studies. The complexes of the lead molecules with the drug receptors were stable in terms of molecular dynamics simulation derived parameters such as root mean square deviation and radius of gyration. The top ten residues contributing significantly to the binding free energies were deciphered through analysis of molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) and molecular mechanics generalized Born surface area (MM-GBSA). Thus, the results of our studies unravel the potential of F. carica bioactive compounds as anticancer candidate molecules against selected macromolecular receptors.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Another study on the effect papaya leaves on breast cancer cells for antiproliferative activity showed a decrease of NF-kB. The presence of flavonoids in papaya extracts caused the reduction of RO3 which impacted the MCF-7, BCL-2, BCL-XL that in turn inhibited the proliferation of breast cancer cell lines (MCF-7) [34][35][36][37][38][39][40]. This is in accordance with the present study stating that Carica seed extract has inhibited the expression of inhibitory kappa B kinase beta expression in lung cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Effect of Carica Seed Extract on Inhibitory Kappa B Kinase Beta and mTOR mRNA Expression in Lung Cancer Cells (A549 Cells)

Azimudin

Preetha

Jayaraman

et al. 2022

JPRI

View full text Add to dashboard Cite

Background: Lung cancer is considered as one of the most common causes for cancer-related death globally. Carica papaya is one of the most well-known traditional medicines to treat diseases, and is also known to treat cancer and help in cancer prevention. The study investigates the effect of Carica seed extract on inhibitory kappa B kinase beta and mTOR mRNA expression in lung cancer cells (A549 cells). Methods: Cell viability test was assessed using MTT assay. mRNA expression of inhibitory kappa B kinase beta and mTOR mRNA was analyzed by real-time PCR. The results was analysed statistically by ANOVA and Duncan multiple range test with graphpad prism version 5 software. p<0.05 was considered significant. Results: It was observed that there wasmaximum inhibition (50%) at 400-500µg/ml of Carica seed extract. It was also found that the fold change over control of mTOR mRNA expression was significant at 500µg/ml of Carica seed extract and the fold change over control of IKKB mRNA expression was significant (p<0.05) at 400µg/ml in cancer cells treated with Carica seed extract. Conclusion: Thus concluding that Carica seed extract has been found to have significant anticancer property on A549 lung cancer cell lines, and can be used as a natural product in combating lung cancer.

show abstract

“…FCL. was shown to improve diabetes and inhibit tumor cell proliferation ( Umar et al, 2013 ; Soltana et al, 2019 ; Zhang et al, 2019 ) and has known antioxidant, anti-inflammatory, and antiapoptotic effects ( Ali et al, 2012 ; Umar et al, 2013 ; Melisa et al, 2014 ; Zhang et al, 2019 ). We found here that FCL.…”

Section: Discussionmentioning

confidence: 99%

Ficus carica L. Attenuates Denervated Skeletal Muscle Atrophy via PPARα/NF-κB Pathway

Dai

Xiang

et al. 2020

Front. Physiol.

View full text Add to dashboard Cite

Treatment options for denervated skeletal muscle atrophy are limited, in part because the underlying molecular mechanisms are not well understood. Unlike previous transcriptomics studies conducted in rodent models of peripheral nerve injury, in the present study, we performed high-throughput sequencing with denervated atrophic biceps muscle and normal (non-denervated) sternocleidomastoid muscle samples obtained from four brachial plexus injury (BPI) patients. We also investigated whether Ficus carica L. (FCL.) extract can suppress denervated muscle atrophy in a mouse model, along with the mechanism of action. We identified 1471 genes that were differentially expressed between clinical specimens of atrophic and normal muscle, including 771 that were downregulated and 700 that were upregulated. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed that the differentially expressed genes were mainly enriched in the GO terms “structural constituent of muscle,” “Z disc,” “M band,” and “striated muscle contraction,” as well as “Cell adhesion molecules,” “Glycolysis/Gluconeogenesis,” “Peroxisome proliferator-activated receptor alpha (PPARα) signaling pathway,” and “P53 signaling pathway.” In experiments using mice, the reduction in wet weight and myofiber diameter in denervated muscle was improved by FCL. extract compared to saline administration, which was accompanied by downregulation of the proinflammatory cytokines interleukin (IL)-1β and IL-6. Moreover, although both denervated groups showed increased nuclear factor (NF)-κB activation and PPARα expression, the degree of NF-κB activation was lower while PPARα and inhibitor of NF-κB IκBα expression was higher in FCL. extract-treated mice. Thus, FCL. extract suppresses denervation-induced inflammation and attenuates muscle atrophy by enhancing PPARα expression and inhibiting NF-κB activation. These findings suggest that FCL. extract has therapeutic potential for preventing denervation-induced muscle atrophy caused by peripheral nerve injury or disease.

show abstract

Antitumoral activity of Ficus carica L. on colorectal cancer cell lines

Cited by 32 publications

References 36 publications

Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets

Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets

Effect of Carica Seed Extract on Inhibitory Kappa B Kinase Beta and mTOR mRNA Expression in Lung Cancer Cells (A549 Cells)

Ficus carica L. Attenuates Denervated Skeletal Muscle Atrophy via PPARα/NF-κB Pathway

Contact Info

Product

Resources

About